Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Waxman

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Family Medicine and Community Health|April 12, 2024
Storylines of family medicine VI: ways of being-in the office with patientsWilliam B Ventres, Leslie A Stone, Lisa A LaVallee, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
European Urology|January 8, 2018
Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Pediatric Transplantation|September 13, 2008
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioningIan M Waxman, Olga Militano, Leah Baldinger, et al.
Bone Marrow Transplantation|June 12, 2012
The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipientsJ B Le Gall, M C Milone, I M Waxman, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.
Science (New York, N.Y.)|April 23, 2026
An unrecognized mode of small particles in the lower stratosphereMing Lyu, Adam T Ahern, Gregory P Schill, et al.
Science Advances|May 13, 2026
Fate of isoprene peroxy radical constrains the urban photochemical regimeMichael A Robinson, Matthew M Coggon, Kelvin H Bates, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialRobert J Motzer, Brian I Rini, David F McDermott, et al.
Family Medicine and Community Health|April 12, 2024
Storylines of family medicine VI: ways of being-in the office with patientsWilliam B Ventres, Leslie A Stone, Lisa A LaVallee, et al.
European Urology|March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell CarcinomaBernard Escudier, Padmanee Sharma, David F McDermott, et al.
European Urology|January 8, 2018
Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Pediatric Transplantation|September 13, 2008
Sequential administration of sargramostim and filgrastim in pediatric allogeneic stem cell transplantation recipients undergoing myeloablative conditioningIan M Waxman, Olga Militano, Leah Baldinger, et al.
Bone Marrow Transplantation|June 12, 2012
The pharmacokinetics and safety of twice daily i.v. BU during conditioning in pediatric allo-SCT recipientsJ B Le Gall, M C Milone, I M Waxman, et al.
The New England Journal of Medicine|September 26, 2015
Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaRobert J Motzer, Bernard Escudier, David F McDermott, et al.
The New England Journal of Medicine|November 18, 2014
Nivolumab in previously untreated melanoma without BRAF mutationCaroline Robert, Georgina V Long, Benjamin Brady, et al.
Science (New York, N.Y.)|April 23, 2026
An unrecognized mode of small particles in the lower stratosphereMing Lyu, Adam T Ahern, Gregory P Schill, et al.
Science Advances|May 13, 2026
Fate of isoprene peroxy radical constrains the urban photochemical regimeMichael A Robinson, Matthew M Coggon, Kelvin H Bates, et al.
Pageof 15